GlassScriptPhysician profile
Tara Ann Pascal
NPI 1154397974
$5,077.35
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,742 · 2022: $1,542 · 2023: $1,030 · 2024: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,793.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,173.39 | 2021-2024 | |
| Novo Nordisk INC | $851.90 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $606.62 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $536.84 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.15 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $165.90 | 2021-2024 | M-M-R II, Gardasil, Gardasil 9 |
| Pfizer INC. | $126.44 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $124.13 | 2023 | |
| Glaxosmithkline, LLC. | $119.33 | 2021-2023 | Shingrix, Arexvy |
| Abbott Laboratories | $115.69 | 2022-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $106.38 | 2021 | |
| Amarin Pharma, INC. | $77.88 | 2021-2022 | |
| Amgen INC. | $75.04 | 2021-2024 | Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $74.31 | 2021-2022 | |
| Lundbeck LLC | $67.11 | 2022-2024 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.90 | 2021-2023 | Xifaxan |
| Otsuka America Pharmaceutical, INC. | $61.55 | 2022-2023 | Rexulti, Abilify Maintena |
| Almatica Pharma LLC | $61.07 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $56.32 | 2021 | |
| Eisai INC. | $48.89 | 2021-2022 | |
| Bausch Health US, LLC | $39.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.30 | 2023 | |
| Boston Scientific Corporation | $33.01 | 2021 | |
| Astellas Pharma US INC | $27.27 | 2024 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $21.74 | 2022 | |
| Exact Sciences Corporation | $21.58 | 2023 | Cologuard Collection Kit |
| Alnylam Pharmaceuticals INC. | $20.80 | 2022 | |
| Supernus Pharmaceuticals, INC. | $19.98 | 2022 | |
| Esperion Therapeutics, INC. | $17.76 | 2021 | |
| Philips North America LLC | $14.87 | 2021 | |
| Inspire Medical Systems, INC. | $14.13 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tara Pascal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.